A One-Two Punch: New Drug Overfeeds—Then Starves—Cancer Cells
The two-step process could help fight other diseases as well The post A One-Two Punch: New Drug Overfeeds—Then Starves—Cancer Cells appeared first on Nautilus .
A novel drug, developed by researchers at the University of Texas, targets cancer cells using a two-step process that overfeeds them with glucose before starving them of energy. This unique approach, described in a paper published in Nature Chemical Biology, could potentially be applied to treat other diseases as well. The drug works by activating the enzyme glycolysis, causing cancer cells to deplete their glucose reserves.
Simultaneously, the drug inhibits the breakdown of fatty acids, preventing the cells from replenishing their energy stores. This dual-action destroys the cells, effectively 'starving' them of the resources they need to survive and grow. The innovative compound, which acts as a smaller, more accessible alternative to antibody-drug conjugates (ADCs), is easier to manufacture and can target proteins inside cells, not just those on the surface.
Study co-author Ken Hsu likened this new drug to a fully-chemical counterpart to ADCs, highlighting its potential advantages in terms of production and targeting capabilities. While further research and testing are necessary, the researchers are optimistic about the drug's ability to 'strike a one-two punch' against cancer cells.
They believe their approach could be adapted for use in other disease treatments, offering a promising avenue for future medical advancements.
Written by urgent.news from Nautilus's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
